EI
NPCE icon

EAM Investors’s Neuropace NPCE Stock Holding History

EAM Investors’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$543K Sell
41,289
-34,511
-46% -$518K 0.06% 260
2025
Q4 		$1.17M Buy
+75,800
New +$1.01M 0.13% 192
2024
Q2 		– Sell
-75,625
Closed -$998K – 316
2024
Q1 		$998K Buy
75,625
+9,484
+14% +$135K 0.16% 170
2023
Q4 		$682K Sell
66,141
-75,475
-53% -$602K 0.12% 199
2023
Q3 		$1.38M Buy
+141,616
New +$829K 0.27% 178

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EAM Investors's NPCE Position: Q1 2026 in Review

EAM Investors reduced its Neuropace (NPCE) stake by 46% in Q1 2026, selling an estimated $518K and leaving 41,289 shares worth $543K. The position accounts for 0.06% of the portfolio, ranked #260.

EAM Investors first reported a position in NPCE in Q3 2023 and has held it in 5 quarters since. The position peaked at $1.38M in Q3 2023. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • EAM Investors held 41,289 shares of Neuropace worth $543K as of Q1 2026.
  • EAM Investors sold 34,511 Neuropace shares in Q1 2026, an estimated $518K.
  • Neuropace made up 0.06% of EAM Investors's portfolio in Q1 2026, its #260 holding.
  • EAM Investors first reported a position in Neuropace in Q3 2023 and has held it in 5 quarters since.
  • EAM Investors's Neuropace position peaked at $1.38M in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.